You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Science Take-Out Kits for Environmental Health Education

    SBC: Science Take-Out, LLC            Topic: NIEHS

    DESCRIPTION provided by applicant Nearly percent of death and disease worldwide is linked to environmental factors WHO therefore it is critical that the general public has basic understanding of how the environment affects their health and how they might protect themselves against environmental exposures Unfortunately environmental health content is typically covered on a very ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Novel Focal Adhesion Kinase autophosphorylation inhibitors against pancreatic cancer

    SBC: CUREFAKTOR PHARMACEUTICALS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Due to the absence of effective therapies, pancreatic cancer is the fourth leading cause of cancer deaths in both men and women. This study focuses on the development of new small molecule inhibitors targeting Focal Adhesion Kinase against pancreatic cancer. Focal Adhesion Kinase (FAK) has been shown to play an important role in tumor cell survival, including p ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Evaluation of TRB-N0224, a Proprietary Chemically-Modified Curumin, for the Treat

    SBC: TRAVERSE BIOSCIENCES, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Traverse Biosciences Inc. is a pre-clinical stage drug development company working to commercialize new chemical entities which act to resolve inflammatory conditions through pleiotropic host-modulation of pathologically unrestrained matrix metalloproteinases (MMPs) and pro-inflammatory cytokines. The company's lead drug candidate, TRB-N0224, is a proprie ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Recombinant Botulinum Neurotoxin for Treatment of Spastic Disorders

    SBC: Cytodel, Inc.            Topic: NINDS

    DESCRIPTION (provided by applicant): Botulinum neurotoxin (BoNT) is the active ingredient in pharmaceutical products like Botox(R) (Allergan), which FDA has approved for therapeutic and aesthetic indications. Because of its inherent toxicity,the dose of BoNT required to treat spasticity disorders in large muscle groups is uncomfortably close to the toxic dose range. ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development and in vitro validation of therapy for mucopolysaccharidosis III

    SBC: Phoenix Nest Inc.            Topic: 105

    DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Using Structuring Interacting RNAs (sxRNAs) as microRNA Inhibitors

    SBC: HocusLocus Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): We propose developing a trans-molecular RNA-switch for scientists to negatively affect the activity of endogenous microRNA for use as a molecular tool or therapeutic, an anti-miR. Since the discovery of miRNA, the creation of effective anti-miRs has been important, first to study and verify miRNA interactions, and, secondly, as a therapeutic tool. But, creating ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Image-guided planning system for skull correction in children with craniosynostos

    SBC: Kitware, Inc.            Topic: NICHD

    DESCRIPTION (provided by applicant): Craniosynostosis is the premature fusion of cranial sutures and occurs in approximately one in 2000 live births. It results in cranial malformation that can lead to elevated intra-cranial pressure, brain growth impairment, and developmental deficiency. The most common treatment option for craniosynostosis is surgery. Currently, surgical treatment planning of cr ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Modified RNA tools and diagnostics for drug abuse

    SBC: ATHGHIN BIOTECHNOLOGY, INC.            Topic: NIDA

    DESCRIPTION (provided by applicant): Project Summary/Abstract RNA modifications are numerous, and range from simple methylation to complex changes such as addition of aminoacylcarbamoyl moieties. These modifications and, the levels at which are present, are emerging as important regulators of biological processes, and perturbations such as chemical or drug exposure can alter the patterns of specif ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Orally available transition state inhibitors for triple negative breast cancer

    SBC: Nanometics LLC            Topic: NCI

    Problem to be Solved: Triple-negative breast cancer (TNBC) is a deadly disease that accounts for 15-20% of all diagnosed breast cancers worldwide. Metastatic relapse of TNBC carries a poorer prognosis and lower survival rate compared to other breast cancersubtypes. Therefore, identifying novel targets and new therapeutics to treat patients diagnosed with TNBC remains a significant priority of the ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Development of an Antigen Capture Assay for Babesia microti

    SBC: Biopeptides, Corp            Topic: NIAID

    DESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...

    STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government